Molecular Pathogenesis of Acromegaly

Pituitary

Volumn 2, Issue 1, 1999, Pages 43-50

  Drange, Marlys R ^a   Melmed, Shlomo ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Acromegaly; Oncogenes; Pituitary adenomas; Tumor suppressor genes

Indexed keywords

HYPOTHALAMUS HORMONE;

ACROMEGALY; ADENOMA; ANIMAL; HUMAN; HYPOPHYSIS TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW;

ACROMEGALY; ADENOMA; ANIMALS; HUMANS; HYPOTHALAMIC HORMONES; PITUITARY NEOPLASMS;

EID: 0033139646     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009917920589     Document Type: Article

References (84)

1. Melmed S. Acromegaly N Engl J Med 1990;322:966-977.
2. Shimon I, Melmed S. Acromegaly: Differential diagnosis and treatment. In Wierman ME, ed. Contemporary Endocrinology, Vol. 3. Diseases of the Pituitary: Diagnosis and Treatment. New Jersey: Humana Press Inc., 1997:135-151.
3. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990;71:1427-1433.
4. Shimon I, Melmed S. Genetic basis of endocrine disease: Pituitary tumor pathogenesis. J Clin Endocrinol Metab 1997;82:1675-1681.
5. Wakabayayashi I, Inokuchi K, Hasegawa O, Sugihara H, Minami S. Expression of growth hormone (GH)-releasing factor gene in GH-producing pituitary adenoma. J Clin Endocrinol Metab 1992;74:357-361.
6. Levy A, Lightman SL. Growth hormone-releasing hormone transcripts in human pituitary adenomas. J Clin Endocrinol Metab 1992;74:1474-1476.
7. Thapar K, Kovacs K, Stefaneanu L, et al. Overexpression of the growth hormone-releasing hormone gene in acromegaly-associated pituitary tumors. An event associated with neoplastic progression and aggressive behaviour. Am J Pathol 1997;151:769-784.
8. Asa SL, Kovacs K, Stefaneanu L, et al. Pituitary mammosomatotroph adenomas develop in old mice transgenic for growth hormone-releasing hormone. Proc Soc Exp Biol Med 1990;193:232-235.
9. Hasimoto K, Koga M, Motomura T, et al. Identification of alternatively spliced messenger ribonucleic acid encoding truncated growth hormone-releasing hormone receptor in human pituitary adenomas. J Clin Endocrinol Metab 1995;80:2933-2939.
10. Levy L, Bourdais J, Mouhieddine OE, et al. Presence and characterization of the somatostatin precursor in normal human pituitaries and in growth hormone secreting adenomas. J Clin Endocrinol Metab 1993;76:85-90.
11. Asa SL, Kovacs K. Pituitary pathology in acromegaly. Endocrinol Metab Clin N Am 1992;21:553-574.
12. Alexander JM, Biller BMK, Bikkal H, et al. Clinically non-functioning pituitary tumors are monoclonal in origin. J Clin Invest 1990;86:336-340.
13. Biller BMK, Alexander JM, Zervas NT, Hedley-Whyte ET, Arnold A, Klibansky A. Clonal origins of adrenocorticotopin-secreting pituitary tissue in Cushing's disease J Clin Endocrinol Metab 1992;75:1303-1309.
14. Asa SL, Kovacs K, Horvath E. et al. Human fetal adenohypophysis. Electron microscopic and ultrastructural immunocytochemical analysis. Neuroendocrinology 1988;48:423-431.
15. Frawley LS, Boockfor FR. Mammosomatotrophs: Presence and functions in normal and neoplastic pituitary tissue. Endoer Rev 1991;12:337-355.
16. Lloyd RV, Cano M, Chandler WF, Barkan AL, Horvath E, Kovacs K. Human growth hormone and prolactin secreting pituitary adenomas analyzed by in situ hybridization. Am J Pathol 1989;134:605-613.
17. Horvath E, Kovacs K. The adenohypophysis. In Kovacs K, Asa SL, eds. Functional Endocrine Pathology. Boston: Blackwell Scientific, 1991;245-281.
18. Kovacs K, Horvath E, Asa SL, et al. Pituitary cells producing more than one hormone. Trends Endocrinol Metab 1989;1:104.
19. Mulchahey JJ, Jaffe RB. Detection of a potential progenitor cell in the human fetal pituitary that secretes both growth hormone and prolactin. J Clin Endocrinol Metab 1988;66: 24-32.
20. Horvath E, Kovacs K, Singer W, et al. Acidophil stem cell adenoma of the human pituitary: Clinicopathologic analysis of 15 cases. Cancer 1981;47:761-771.
21. Li J, Stefaneanu L, Kovacs K, Horvath E, Smyth HS. Growth hormone (GH) and prolactin (PRL) gene expression and immunoreactivity in GH- and PRL-producing human pituitary adenomas. Virchows Arch A Pathol Anat Histopathol 1993;422:193-201.
22. Beck-Peccoz P, Piscitelli G, Amr S, et al. Endocrine, biochemical, and morphological studies of a pituitary adenoma secreting growth hormone, thyrotropin (TSH), and alpha-subunit: Evidence for secretion of TSH with increased bioavailability. J Clin Endocrinol Metab 1986;62:704-711.
23. Furuhata S, Kameya T, Tsuruta T, Naritaka H, Toya S. Colocalization of growth hormone (GH) and glycoprotein subunit alpha in GH-producing pituitary adenomas in acromegalic patients. Acta Neuropathol 1994;87:568-571.
24. Felix I, Asa SL, Kovacs K, Horvath E, Smyth HS. Recurrent plurihormonal bimorphous pituitary adenoma producing growth hormone, thyrotropin, and prolactin. Arch Pathol Lab Med 1994;118:66-70.
25. Cooper GM. Oncogenes, 2nd edition, Boston: Jones and Bartlett, 1995.
26. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. GTPase inhibiting mutations activate the a chain of GS and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989;340:692-696.
27. Lyons J, Landis CA, Harsh G, et al. Two G protein oncogenes in human endocrine tumors. Science 1990;249:655-659.
28. Spada A, Vallar L. G-protein oncogenes in acromegaly. Horm Res 1992;38:90-93.
29. sα in growth hormone-secreting pituitary adenomas by the polymerase chain reaction-direct sequencing method using paraffin-embedded tissues. Acta Endocrinol 1993;129: 301-306.
30. Yang I, Park S, Ryu M, et al. Characteristics of gsp-positive growth hormone-secreting pituitary tumors in Korean acromegalic patients. Eur J Endocrinol 1996;134:720-726.
31. Spada A, Arosio M, Cochicchio D, et al. Clinical, biochemical and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 1990;71:1421-1426.
32. Adams EF, Brockmeier S, Friedmann E, Roth M, Buchfelder M, Fahlbusch R. Clinical and biochemical characteristics of acromegalic patients harboring gsp-positive and gsp-negative pituitary tumors. Neurosurgery 1993;33:198-203.
33. Barlier A, Gunz G, Zamora AJ, et al. Prognostic and therapeutic consequences of GS alpha mutations in somatotroph adenomas. J Clin Endocrinol Metab 1998;83:1604-1610.
34. Lania A, Persani 1, Ballare E, Mantovani S, Losa M, Spada A. Constitutively active Gsα is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas. J Clin Endocrinol Metab 1998;83: 1624-1628.
35. Struthers RS, Vale WW, Arias C, Sawchenko PE, Montminy MR. Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant. Nature 1991;350:622-624.
36. Bertherat J, Chanson P, Montminy M. The cyclic adenosine 3′,5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol Endocrinol 1995;9:777-783.
37. Pei L, Melmed S, Scheithauer B, Kovacs K, Prager D. H-ras mutations in human pituitary carcinoma metastasis. J Clin Endocrinol Metab 1994;78:842-846.
38. Cai WY, Alexander JM, Hedley-Whyte ET, et al. Ras mutations in human prolactinomas and pituitary carcinomas. J Clin Endocrinol Metab 1994;78:89-93.
39. Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1997;11:433-441.
40. Zhang X, Horwitz GA, Prezant TR, et al. Stucture, expression, and function of human pituitary tumor transforming gene (PTTG). Mol Endocrinol 1999;13:156-166.
41. Strausberg RL, Dahl CA, Klausner RD. New opportunities for uncovering the molecular basis of cancer. Nature Gen 1997;15(Special No.):415-416.
42. Zhang X, Horwitz GA, Heaney A, Prezant TR, Melmed S. Pituitary tumor transforming gene (PTTG) expression in pituitary adenomas: Marker for functional tumor invasiveness. J Clin Endocrinol Metab 1999;84:761-767.
43. Wilson CB. Role of surgery in management of pituitary tumors. Neurosurg Clin N Am 1990;1:139-159.
44. Benedict WF, Xu H Hu S, Takahashi R. Role of the retinoblastoma gene in the initiation and progression of human cancer. J Clin Invest 1990;5:988-993.
45. Jacks T, Fazeli A, Schmitt EM. Bronson RT, Goodell MA and Weinberg RA. Effect of an RB mutation in the mouse. Nature 1992;359:295-299.
46. Pei L, Melmed S, Scheithauer B, Kovacs K, Benedict WF, and Prager D. Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: Evidence for a chromosome 13 tumor suppressor gene other than RB. Cancer Res 1995;55:1613-1616.
47. Woloschak M, Yu A, Xiao J, Post KD. Abundance and state of phosphorylation of the retinoblastoma gene product in human pituitary. Int J Cancer 1996;67:16-19.
48. Cryns VL, Alexander JM, Klibanski A, Arnold A. The retinoblastoma gene in human pituitary tumors. J Clin Endocrinol Metab 1993;77:644-646.
49. Zhu J, Leon SP, Beggs AH, Busque L, Gilliland DG, Black PM. Human pituitary adenomas show no loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus. J Clin Endocrinol Metab 1994;78:922-927.
50. Woloschak M, Roberts JL, Post KD. Loss of heterozygosity at the retinoblastoma gene locus in human pituitary tumors. Cancer 1994;74:693-696.
51. Pearce SH, Trump D, Wooding C, Sheppard MN, Clayton RN, Thakker RV. Loss of heterozygosity studies at the retinoblastoma and breast cancer susceptability (BRCA2) loci in pituitary, parathyroid, pancreatic and carcinoid tumours. Clin Endocrinol 1996;45:195-200.
52. Herman V, Drazin NZ, Gonsky R, Melmed S. Molecular screening of pituitary adenomas for gene mutations and rearrangements. J Clin Endocrinol Metab 1993;77:50-55.
53. Levy A, Hall 1, Yeudall WA, Lightman SL. p53 gene mutations in pituitary adenomas: Rare events. Clin Endocrinol 1994;41:809-814.
54. Pernicone, PJ, Scheithauer BW, Sebo TJ, et al. Pituitary carcinoma: A clinicopathologic study of 15 cases. Cancer 1997;79:804-812.
55. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 1996;38:763-770.
56. Kaghad M, Bonnet H, Yang A, et al. Monoallellelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-819.
57. Mai M, Huang H, Reed C, et al. Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. Genomics 1998;51:359-363.
58. Williamson C, Pannett AA, Pang JT, et al. Localisation of a gene causing endocrine neoplasia to a 4 cM region on chromosome 1p35-p36. J Med Genet 1997;34:617-619.
59. INK4a gene product in human pituitary tumors. Cancer Res 1996;56:2493-2496.
60. Farrell WE, Simpson DJ, Bicknell JE, Talbot AJ, Bates AS, Clayton RN. Chromosome 9p deletions in invasive and non-invasive nonfunctional pituitary adenomas: The deleted region involves markers outside of the MTS1 and MTS2 genes. Cancer Res 1997;57:2703-2909.
61. Yoshimoto K, Tanaka C, Yamada S, et al. Infrequent mutations of p16INK4a and P15INK4b genes in human pituitary adenomas. Eur J Endocrinol 1997;136:74-80.
62. Woloschak M, Yu A, Post KD. Frequent inactivation of the p16 gene in human pituitary tumors by gene methylation. Mol Carcin 1997;19:221-224.
63. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996; 85:707-720.
64. kip1. Cell 1996;85:721-732.
65. kip1-deficient mice. Cell 1996; 85:733-744.
66. Lloyd RV, Jin L, Qian X, Kulig E. Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol 1997; 150:401-407.
67. Dahia PL, Aguiar RC, Honegger J, et al. Mutation and expression analysis of the p27/kip1 gene in corticotrophin-secreting tumours. Oncogene 1998;16:69-76.
68. Tanaka C, Yoshimoto K, Yang, et al. Infrequent mutations of p27Kip1 gene and trisomy 12 in a subset of human pituitary adenomas. J Clin Endocrinol Metab 1997;82:3141-3147.
69. Weinstein LS, Shenker A, Gejman P, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991;325:1688-1695.
70. Chanson P, Kib A, Visot A, Derome PJ. McCune-Albright syndrome and acromegaly: clinical studies and responses to treatment in five cases. Eur J Endocrinol 1994;131:229-234.
71. Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988; 322:85-87.
72. Fujimori M, Wells SA, Nakamura Y. Fine mapping of the gene responsible for multiple endocrine neoplasia type 1 (MEN1). Am J Hum Genet 1992;55:399-403.
73. Chandrasekharappak SC, Guru SC Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404-406.
74. Guru SC, Godsmith PK, Burns AL, et al. Menin, the product of the MEN1 gene, is a nuclear protein Proc Natl Acad Sci 1998;95:1630-1634.
75. Zhuang Z, Ezzat SZ, Vortmeyer AO, et al. Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res 1997;57:5446-5451.
76. Prezant T, Levine J, Melmed S. Molecular characterization of the Men1 tumor suppressor gene in sporadic pituitary tumors. J Clin Endocrinol Metab 1998;83:1388-1391.
77. Tanaka C, Kimura T, Yang P, et al. Analysis of loss of heterozygosity on chromosome 11 and infrequent inactivation of MEN1 gene in sporadic pituitary adenomas. J Clin Endocrinol Metab 1998;83:2631-2634.
78. Benlian P, Giraud S, Lahlou N, et al. Familial acromegaly: A specific clinical entity - further evidence from the genetic study of a three-generation family. Eur J Endocrinol 1995; 133:451-456.
79. Yamada S, Yoshimoto K, Sano T, et al. Inactivation of the tumor suppressor gene on 11q13 in brothers with familial acrogigantism without multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 1997;82:239-242.
80. Tanaka C, Katsuhiko Y, Shozo Y, et al. Absence of germ-line mutations of the multiple endocrine neoplasia type 1 (MEN1) gene in familial pituitary adenomia in contrast to MEN1 in Japanese. J Clin Endocrinol Metab 1998;83: 960-965.
81. Teh BT, Rarnebo F, Phelan C, et al. Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type 1, familial acromegaly and familial isolated hyperparathyroidism. J Clin Endocrinol Metab 1998;83:2621-2626.
82. Carney JA, Hrudka LS, Beauchamp GD, Gordon H. Dominant inheritance of the complex of myxomas, spotty pigmentation, and endocrine overactivity. Mayo Clin Proc 1986; 61:165-172.
83. Stratakis CA, Carney JA, Lin JP, et al. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Invest 1996;97:699-705.
84. Stratakis CA, Jenkins RB, Pras E, et al. cytogenetic and microsatellite alterations in tumors from patients with the syndrome of myxomas, spotty skin pigmentation and endocrine overactivity (Carney complex). J Clin Endocrinol Metab 1996;81:3607-3614.